Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988203 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
A Phase 1 study of Monkeypox, sponsored by BioNTech SE.
- Active
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 8
- Study locations
NCT05988203 is a Phase 1 study of Monkeypox that is active but no longer recruiting, run by BioNTech SE. The registered enrollment target is 96 participants, below the 260-participant average among 3 other Monkeypox trials with a reported enrollment target (63% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05988203, a Phase 1 study of Monkeypox, is active but no longer recruiting, sponsored by BioNTech SE.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox). This study started with substudy A (SSA) and substudy B (SSB) for which recruitment has been completed. A Substudy C (SSC) was planned, but the sponsor decided not to conduct it. This study will therefore continue with substudy D (SSD). In SSA and SSB, dosing started with an initial sentinel group, followed by the expansion cohort. This study was initially planned to investigate two vaccine candidates (the quadrivalent BNT166a and the trivalent BNT166c). The sponsor decided to not activate the groups with BNT166c.
Conditions Studied
Interventions
- BIOLOGICAL BNT166a
Study Locations (8)
Other
- Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust - Cambridge
- Royal Surrey County Hospital Foundation Trust, NIHR Royal Surrey Clinical Research Facility - Guildford
- Guy's and St Thomas' NHS Foundation Trust of St Thomas' Hospital - London
- University Hospital Southampton - Southampton
California
- California Research Foundation - San Diego
Missouri
- Alliance for Multispecialty Research, LLC - Kansas City
Tennessee
- Alliance for Multispecialty Research, LLC - Knoxville
Washington
- University of Washington Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05988203
The ClinicalTrials.gov registry entry for NCT05988203 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 3 other Monkeypox trials with a reported enrollment target (63% lower). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Monkeypox appearing as the primary indexed condition, and to 1 intervention - of which BNT166a is the first listed.
NCT05988203 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT05988203 about?
NCT05988203 is a clinical study titled "A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines". This is a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox). This study started with substudy A (SSA) and substudy B (SSB) f...
What is the current status of trial NCT05988203?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2023-09-21. Estimated completion is 2026-03.
What conditions does trial NCT05988203 study?
This clinical trial studies the following conditions: Monkeypox.
What interventions are being tested in trial NCT05988203?
The interventions under investigation include: BNT166a (BIOLOGICAL).
Who is sponsoring clinical trial NCT05988203?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988203 being conducted?
This trial has 8 study locations across California, Missouri, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monkeypox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
RECRUITING
-
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
COMPLETED · Phase 2
-
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.